Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus

  1. Lisa Opipari-Arrigan1,
  2. Emily M Fredericks1,*,
  3. Nugget Burkhart2,
  4. Linda Dale2,
  5. Mary Hodge2,
  6. Carol Foster2

Article first published online: 21 NOV 2007

DOI: 10.1111/j.1399-5448.2007.00283.x

Issue

Pediatric Diabetes

Pediatric Diabetes

Volume 8, Issue 6, pages 377–383, December 2007

Additional Information

How to Cite

Opipari-Arrigan, L., Fredericks, E. M., Burkhart, N., Dale, L., Hodge, M. and Foster, C. (2007), Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatric Diabetes, 8: 377–383. doi: 10.1111/j.1399-5448.2007.00283.x

Author Information

  1. 1

    Division of Child Behavioral Health, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA

  2. 2

    Division of Endocrinology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA

*Emily M Fredericks, PhD 1931 Taubman Center Box 0318 1500 E. Medical Center Drive Ann Arbor, MI 48109-0318 USA. Tel: (734) 936-4220; fax: (734) 936-6897; e-mail: emfred@med.umich.edu

Publication History

  1. Issue published online: 21 NOV 2007
  2. Article first published online: 21 NOV 2007
  3. Submitted 12 April 2006. Accepted for publication 16 November 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (89K)

Keywords:

  • child;
  • insulin infusion systems;
  • preschool;
  • quality of life;
  • T1DM

Objective:  To compare medical, nutritional, and psychosocial outcomes of continuous subcutaneous insulin infusion (CSII) therapy and multiple daily insulin injections (MDI) in preschoolers with type 1 diabetes mellitus (T1DM) in a randomized controlled trial.

Study design:  Sixteen children (mean age 4.4 ± 0.7 yr, range 3.1–5.3 yr) with T1DM were randomly assigned to CSII or MDI. Hemoglobin A1c (HbA1c) was measured monthly for 6 months. Glucose variability was measured at baseline and at 6 months using continuous blood glucose sensing. Quality of life, adverse events, and nutrition information were assessed.

Results:  Parents of the CSII group reported a significant decrease in diabetes-related worry, while parents of the MDI group reported an increased frequency of stress associated with their child’s medical care. Mean HbA1c levels from baseline (CSII 8.3 ± 1.4%, MDI 8.0 ± 0.8%) to 6 months (CSII 8.4 ± 0.8%, MDI 8.2 ± 0.4%) remained stable, and group differences were not significant. There were no significant group differences in duration of hypo- or hyperglycemic events or frequency of adverse events.

Conclusion(s):  For young children with T1DM, CSII therapy is comparable to MDI therapy with regard to glucose control but is associated with higher treatment satisfaction and improved quality of life.

View Full Article (HTML) Get PDF (89K)